What BioPharma Services does

BioPharma Services Inc. is a privately held, full-service Contract Research Organization (CRO) headquartered in Toronto, Ontario, Canada. The company executes Phase 1/2a clinical trials, bioequivalence and bioavailability (BE/BA) studies for generic and 505(b)(2) New Drug Applications, Human Abuse Potential studies, and an emerging set of PET/neuroimaging and psychedelic clinical trials. It serves global pharmaceutical and biotechnology sponsors, with regulatory inspection coverage spanning the US FDA, UK MHRA, ANSM (France), DKMA (Denmark), ANVISA (Brazil), and Health Canada, and holds GLP certification from the Standards Council of Canada.

The technical platform centers on a 150-bed Toronto clinical facility paired with a bioanalytical laboratory equipped with LC/MS/MS instrumentation for sensitive drug quantification, alongside CDISC-compliant data management, biostatistics, pharmacokinetics, scientific affairs, medical writing, and protocol development capabilities. The company has accumulated approximately 2,200-2,500 completed bioequivalence and Phase I clinical trials across therapeutic areas including neurology, cardiology, immunotherapies, and infectious diseases.

Commercially, BioPharma Services operates a B2B enterprise sales model through a dedicated Sponsor Sales team and discovery-call engagement, billing on a project/study basis with quote-based pricing negotiated per protocol. Revenue is generated from study fees, per-subject costs, and integrated support service engagements. The company is founder-owned (by two surgeons) with no disclosed external funding rounds or institutional investors, and reported 251-500 employees. A November 2025 ransomware incident and subsequent February 2026 dark-web data disclosure involving study participant personal health information constitute the principal recent operational and reputational risks.

Name

BioPharma Services

Legal name

BioPharma Services Inc.

Website

https://biopharmaservices.ca

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

251–500 employees

Short description

BioPharma Services Inc. is a privately held, Toronto-based full-service Contract Research Organization (CRO) executing Phase 1/2a trials, bioequivalence/bioavailability studies, and human abuse potential studies for global pharmaceutical and biotech sponsors, supported by an in-house LC/MS/MS bioanalytical lab and 150-bed clinical facility.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) Services

NAICS

Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Toxicology & Safety Assessment CROs (GLP) (HLAGAAAC), Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD), Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF), Pharmacovigilance, Risk Management & Medical Affairs CROs (HLAGAAAH)

Keywords

• Contract research organization
• Phase 1 clinical trials
• Bioequivalence studies
• Bioanalytical services
• Human abuse potential studies

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Clinical Research Services: BioPharma Services generates revenue through providing clinical trial services to pharmaceutical and biotech companies. As a CRO, they charge for the conduct of clinical studies including Phase 1 trials, bioequivalence studies, human abuse potential studies, and related support services. Revenue is generated through study fees, per-subject costs, and professional service engagements. The company operates on a project-based billing model where sponsors pay for clinical trial execution, data management, bioanalysis, and regulatory support services.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

BioPharma Services Inc. is a full-service Contract Research Organization (CRO) that conducts early-phase clinical research for pharmaceutical and biotech sponsors. Its core offerings are Phase 1/2a clinical trials, Bioequivalence/Bioavailability (BE/BA) studies, and Human Abuse Potential (HAP) studies, delivered alongside integrated support services such as bioanalysis (LC/MS/MS), pharmacokinetics, CDISC-compliant data management, biostatistics, medical writing, scientific affairs, and subject recruitment from a 150-bed Toronto clinical facility.

Product overview

BioPharma Services Inc. is a full-service Contract Research Organization (CRO) offering a unified platform of clinical trial services centered on Phase 1/2a clinical trials, Bioequivalence/Bioavailability (BE/BA) studies, and Human Abuse Potential studies as core offerings. These core services are complemented by an integrated suite of support services including Bioanalysis & Bioanalytical Services, Pharmacokinetics Studies, Clinical Trial Data Management, Biometrics with CDISC standards, Medical Writing, Scientific Affairs, Clinical Trial Recruitment, and PET/Psychedelic Clinical Trials. The company operates from facilities in Toronto, Ontario with 150-bed capacity and serves global pharmaceutical clients across multiple therapeutic areas including neurology, cardiology, immunotherapies, and infectious diseases.

Differentiator

Problem solved

Functional benefit

Products and services

• Phase 1 & 2a Clinical Trials Early-phase clinical trial services for global pharmaceutical sponsors across therapeutic areas including neurology, cardiology, immunotherapies, and infectious diseases.
• Bioequivalence & Bioavailability Studies BE and BA studies to support generic and hybrid drug filings and 505(b)(2) New Drug Applications for sponsors targeting multiple regulatory markets.
• Human Abuse Potential Studies Clinical studies on opioids, narcotics, and cannabinoid products to characterize abuse liability and inform regulatory submissions.
• Bioanalysis & Bioanalytical Services Quantitative bioanalytical testing using LC/MS/MS platforms with novel assay development and expedited turnaround for clinical and preclinical samples.
• Pharmacokinetics Studies PK study design and analysis supporting drug submissions to multiple regulatory markets, led by the Chief Scientific Officer.
• Clinical Trial Data Management Data management services meeting current regulatory and industry standards for clinical trial datasets.
• Biometrics & CDISC Standards Biostatistical services using CDISC-compliant data standards from data collection through regulatory submission.
• Medical Writing Medical writing services to support clear communication between subjects, sites, sponsors, and regulatory agencies.
• Scientific Affairs In-house scientific consulting across diverse clinical drug development programs and multiple therapeutic areas.
• Clinical Trial Recruitment Subject recruitment services leveraging a database of engaged healthy volunteers, including special populations.
• PET Clinical Trials & Neuroimaging PET CNS First-in-Human trials, PET clinical and imaging site coordination, and molecular imaging services for CNS programs.
• Psychedelic Clinical Trials Clinical trial services for psychedelic programs, including high-dose and microdosing studies and psilocybin/psilocin method development.
• Functional Services Provider (FSP) FSP consulting engagements providing functional clinical trial support staff and services for sponsors.

Quantifiable outcome

• 2,200+ completed clinical trials demonstrating track record and execution capability
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Fortrea (formerly Labcorp Drug Development): Fortrea is a large clinical CRO spun out from Labcorp with early-phase, bioanalytical, and central laboratory capabilities. Operates overlapping services to BioPharma across the global Phase 1 and BE market.
• ICON plc: ICON is one of the largest global CROs, offering full Phase 1 through Phase 4 services including early-phase clinical pharmacology and bioanalytical labs (post-PRA merger). It competes with BioPharma in Phase 1/bioequivalence but at vastly greater scale.
• IQVIA: IQVIA is the largest global CRO with extensive early-phase clinical pharmacology, bioanalytical, and bioequivalence operations worldwide. Sets the competitive ceiling BioPharma must differentiate against in Phase 1 and BE work.
• Parexel International: Parexel is a top-tier global CRO with early-phase clinical pharmacology, bioanalysis, and regulatory services as part of a broad Phase 1-4 portfolio. Competes with BioPharma on Phase 1 and BE studies but primarily targets large pharma sponsors.
• Syneos Health: Syneos Health is a large global biopharmaceutical services organization offering clinical development (including early-phase) and commercial services. It is a broad incumbent that includes Phase 1 capacity competing with BioPharma.

Direct peers

• Celerion: Celerion is a Phase 1 clinical research CRO offering bioequivalence, early-phase clinical trials, and bioanalytical services. It is the most directly comparable peer to BioPharma Services given overlapping focus on early-phase studies, BE/BA, and bioanalysis with similar therapeutic-area breadth.
• Novum Pharmaceutical Research Services: Novum is a niche Phase 1 clinical CRO specializing in bioequivalence and early-phase studies for generic and innovator drugs. Highly comparable to BioPharma in target customer base and service focus.
• Quotient Sciences: Quotient Sciences operates a Translational Pharmaceutics platform integrating formulation, manufacturing, and clinical testing including bioequivalence and first-in-human studies. The Phase 1 and BE focus plus integrated service model directly mirrors BioPharma's positioning.
• Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-sized global CRO with strong early-phase and bioequivalence offerings alongside later-phase services. It competes with BioPharma for Phase 1 and BE study sponsors across multiple therapeutic areas.
• CTI Clinical Trial & Consulting Services: CTI Clinical Trial is a mid-sized CRO with early-phase and bioequivalence capabilities similar to BioPharma, including therapeutic expertise in specialty areas such as immunology and rare diseases. Comparable in scale and service mix.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCuMfcBpHgI8mJQhs872ycmg/featured
• LinkedInlinkedin.com/company/473962
• Xx.com/_biopharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioPharma Services